Coherus Oncology, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
CHRS$0.64-21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended · · Nine Months Ended | ||||||||||||
| · · September 30, · · September 30, | ||||||||||||
| · · 2026 · · 2025 · · 2026 · · 2025 | ||||||||||||
| Net revenue | | $14,274 | | $11,571 | | $40,891 | | $29,424 | ||||
| Costs and expenses: | | | | | | | | | | |||
| Cost of goods sold | | 4,092 | | 3,721 | | 12,148 | | | 9,769 | |||
| Research and development | | 22,606 | | 27,252 | | 65,591 | | | 77,914 | |||
| Selling, general and administrative | | 21,225 | | 24,931 | | 65,283 | | | 76,995 | |||
| Total costs and expenses | | 47,923 | | 55,904 | | 143,022 | | 164,678 | ||||
| Loss from operations | | (33,649) | | (44,333) | | (102,131) | | | (135,254) | |||
| Interest expense | | (2,781) | | (2,325) | | (7,290) | | (6,752) | ||||
| Loss on debt extinguishment | | | (3,363) | | | — | | | (3,363) | | | — |
| Other income (expense), net | | 918 | | 2,141 | | 3,627 | | 5,229 | ||||
| Loss from continuing operations before income taxes | | (38,875) | | (44,517) | | (109,157) | | | (136,777) | |||
| Income tax provision | | — | | — | | — | | — | ||||
| Net loss from continuing operations | | | (38,875) | | | (44,517) | | | (109,157) | | | (136,777) |
| Net income (loss) from discontinued operations, net of tax (Note 6) | | | (459) | | | 8,986 | | | 10,865 | | 342,444 | |
| Net income (loss) | | $(39,334) | | $(35,531) | | $(98,292) | | $205,667 | ||||
| | | | | | | | | | | | | |
| Net loss per share from continuing operations - basic and diluted | | $(0.25) | | $(0.38) | | $(0.73) | | $(1.18) | ||||
| Net income (loss) per share from discontinued operations - basic and diluted | | $(0.00) | | $0.08 | | $0.07 | | $2.95 | ||||
| Net income (loss) per share - basic and diluted | | $(0.25) | | $(0.31) | | $(0.66) | | $1.77 | ||||
| | | | | | | | | | | | | |
| Weighted-average number of shares used in computing net income (loss) per share: | | | | | | | | | | | | |
| Basic and diluted | | | 154,970,687 | | | 116,229,170 | | | 148,796,665 | | | 116,056,247 |
| | | | | | | | | | | | | |
| Comprehensive income (loss): | | | | | | | | | | | | |
| Net income (loss) | | $(39,334) | | $(35,531) | | $(98,292) | | $205,667 | ||||
| Other comprehensive loss: | | | | | | | | | | | | |
| Unrealized gain (loss) on available-for-sale securities, net of tax | | | (9) | | | 72 | | | (95) | | | 72 |
| Foreign currency translation adjustments, net of tax | | | 3 | | | — | | | 3 | | | — |
| Comprehensive income (loss) | | $(39,340) | | $(35,459) | | $(98,384) | | $205,739 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.